Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $35.71.

Several research firms have commented on DAWN. JPMorgan Chase & Co. decreased their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday.

Day One Biopharmaceuticals Stock Performance

DAWN stock opened at $14.65 on Friday. The company has a market capitalization of $1.29 billion, a PE ratio of -14.22 and a beta of -1.51. Day One Biopharmaceuticals has a one year low of $10.90 and a one year high of $18.07. The company’s 50 day moving average price is $14.19 and its two-hundred day moving average price is $14.39.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period last year, the business posted ($0.54) earnings per share. On average, research analysts predict that Day One Biopharmaceuticals will post -1.65 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 2,232 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $31,248.00. Following the sale, the insider now owns 1,127,535 shares in the company, valued at $15,785,490. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Jeremy Bender sold 10,681 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $149,534.00. Following the sale, the chief executive officer now owns 98,932 shares in the company, valued at approximately $1,385,048. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 2,232 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $31,248.00. Following the sale, the insider now owns 1,127,535 shares in the company, valued at approximately $15,785,490. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,748 shares of company stock worth $689,072 over the last quarter. Corporate insiders own 8.40% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds have recently modified their holdings of the business. SteelPeak Wealth LLC boosted its holdings in shares of Day One Biopharmaceuticals by 9.8% during the 3rd quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after buying an additional 1,550 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 87.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,203 shares of the company’s stock worth $267,000 after purchasing an additional 8,935 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after purchasing an additional 1,002 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in Day One Biopharmaceuticals in the 3rd quarter worth about $2,566,000. Finally, Handelsbanken Fonder AB boosted its stake in Day One Biopharmaceuticals by 16.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock worth $376,000 after purchasing an additional 3,900 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.